We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Lexicon Pharmaceuticals Inc | NASDAQ:LXRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.765 | 1.75 | 1.85 | 9 | 09:53:07 |
From May 2023 to May 2024
By Sabela Ojea
Lexicon Pharmaceuticals said Friday that the Food and Drug Administration has approved its Inpefa treatment, aimed at reducing heart failures.
The biopharmaceutical company said Inpefa is expected to be commercially available in the U.S. market by the end of June.
Inpefa, a once-daily oral tablet known generically as sotagliflozin, targets the risk of cardiovascular death, urgent heart failure medical visits and hospitalizations in adults with heart failure of type 2 diabetes mellitus and chronic kidney disease, among other cardiovascular risk factors.
Shares rose 0.9% to $3.21 in after-hours trading.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 26, 2023 16:34 ET (20:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Lexicon Pharmaceuticals Chart |
1 Month Lexicon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
